蔚蓝生物：公司及子公司联合申报的米氮平软膏获批新兽药注册证书

Core Viewpoint - The company announced the approval of "Mirtazapine Ointment" as a new veterinary drug, which is expected to create a new growth point for its business [1] Group 1: Product Development - The product "Mirtazapine Ointment" is classified as a Category V new veterinary drug [1] - The ointment is primarily used for controlling weight loss in cats [1] - The research and development of this product involved collaboration with multiple units and a total investment of 1.8622 million yuan [1] Group 2: Business Impact - The acquisition of the new veterinary drug registration certificate is anticipated to contribute positively to the company's performance [1]